Related Experiment Video

Updated: May 17, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Drug therapy for children with tuberculosis

L Peter Ormerod1

  • 1Chest Clinic, Royal Blackburn Hospital, Blackburn, Lancashire, UK. Lawrencve.Ormerod@elht.nhs.uk

Archives of Disease in Childhood
|October 30, 2012
PubMed

Insights

Pediatric tuberculosis (TB) drug treatment relies on adult data, necessitating careful diagnosis to differentiate active TB disease from infection. New TB drugs require pediatric testing, as current dosing for children remains a challenge.

Area of Science:

  • Pediatric infectious diseases
  • Pharmacology
  • Public health

Background:

  • Current pediatric tuberculosis (TB) drug treatment protocols are primarily derived from adult studies.
  • Diagnosing and treating asymptomatic TB infection in children requires excluding active TB disease first.
  • Screening of contacts often identifies children with active TB disease, even if asymptomatic.

Purpose of the Study:

  • To review the current landscape of drug treatment for pediatric tuberculosis (TB) disease and infection.
  • To highlight the challenges and gaps in pediatric TB drug therapy, including extrapolation from adult data and pharmacokinetic issues.
  • To discuss the implications of new drug development for children with TB.

Main Methods:

  • Literature review of existing studies on pediatric TB treatment.
  • Analysis of data extrapolation from adult TB trials to pediatric populations.
  • Examination of pharmacokinetic and dosing challenges for current TB drugs in children.

Main Results:

  • Pediatric TB treatment is largely based on adult data, with limited specific pediatric trials.
  • A significant proportion of children with active TB are identified through contact screening.
  • New TB drugs are under development but lack pediatric testing, necessitating reliance on adult data extrapolation.

Conclusions:

  • There is a critical need for pediatric-specific TB drug trials and pharmacokinetic studies.
  • Current treatment strategies for children with TB infection and disease require careful consideration of adult data limitations.
  • Addressing pharmacokinetic and dosing issues, particularly for isoniazid, is essential for effective pediatric TB management.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories: